{"id":"NCT01308567","sponsor":"Sanofi","briefTitle":"Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer","officialTitle":"Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m^2 and at 20 mg/m^2 in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-05-05","primaryCompletion":"2015-09","completion":"2018-05","firstPosted":"2011-03-04","resultsPosted":"2017-03-03","lastUpdate":"2019-06-05"},"enrollment":1168,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Cabazitaxel (XRP6258)","otherNames":[]},{"type":"DRUG","name":"Docetaxel (XRP6976)","otherNames":[]},{"type":"DRUG","name":"Prednisone","otherNames":[]}],"arms":[{"label":"Cabazitaxel 25 mg/m^2","type":"EXPERIMENTAL"},{"label":"Cabazitaxel 20 mg/m^2","type":"EXPERIMENTAL"},{"label":"Docetaxel 75 mg/m^2","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\n* To demonstrate the superiority of cabazitaxel plus prednisone at 25 mg/m\\^2 (Arm A) or 20 mg/m\\^2 (Arm B) versus docetaxel plus prednisone (Arm C) in term of overall survival (OS) in participants with metastatic castration resistant prostate cancer (mCRPC) and not previously treated with chemotherapy.\n\nSecondary Objectives:\n\n* To evaluate safety in the 3 treatment arms.\n* To compare efficacy of cabazitaxel at 20 mg/m\\^2 and 25 mg/m\\^2 to docetaxel for:\n\n  * Progression Free Survival (PFS) (RECIST 1.1)\n  * Tumor progression free survival (RECIST 1.1)\n  * Tumor response in participants with measurable disease (RECIST 1.1),\n  * PSA response\n  * PSA-Progression free survival (PSA-PFS).\n  * Pain response in participants with stable pain at baseline\n  * Pain progression free survival\n  * Time to occurrence of any skeletal related events (SRE)\n* To compare Health-Related Quality of Life (HRQL).\n* To assess the pharmacokinetics and pharmacogenomics of cabazitaxel.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Baseline up to death or study cut-off date, whichever was earlier (maximum duration: 51 months )","effectByArm":[{"arm":"Docetaxel 75 mg/m^2","deltaMin":24.3,"sd":null},{"arm":"Cabazitaxel 20 mg/m^2","deltaMin":24.5,"sd":null},{"arm":"Cabazitaxel 25 mg/m^2","deltaMin":25.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.7574"},{"comp":"OG000 vs OG001","p":"0.9967"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":167,"countries":["United States","Australia","Belarus","Brazil","Canada","China","Czechia","Denmark","Finland","France","Germany","Israel","Italy","Japan","Mexico","Peru","Poland","Portugal","Romania","Russia","Spain","Sweden","Taiwan","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["38364191","33740734","29500065","28753384","24722180","23228299"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":126,"n":387},"commonTop":["Diarrhoea","Fatigue","Nausea","Asthenia","Constipation"]}}